ECE2018 Poster Presentations: Adrenal and Neuroendocrine Tumours Adrenal cortex (to include Cushing's) (70 abstracts)
Prevalance of primary aldosteronism in hypertensive patients: epidemiological data from a tertiary centre
Nikolaos Voulgaris 1 , Labrini Papanastasiou 1 , Sofia Vlachou 1 , Evangelia Kyriazi 1 , Ernestini Tyfoxylou 1 , Nikoletta Monastirioti 1 , Chara Kapsali 1 , Liana Charalampidou 1 , Zachaki Aglaia 1 , Athanasia Kalantzi 1 , Christos Gravvanis 1 , Athina Markou 1 , Eirini Giagourta 1 , Theodora Kounadi 1 , Eva Kassi 2 , Gregory Kaltsas 3 & George Piaditis 1
1Department of Endocrinology and Diabetes Center, ‘G Gennimatas’ General Hospital, Athens, Greece; 2Department of Biological Chemistry, Medical Scholl, National and Kapodistrian University of Athens, Athens, Greece; 3Department of Pathophysiology, Laikon Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Introduction: Primary aldosteronism (PA) is the most common cause of endocrine hypertension. Its prevalence varies from 5-15%, which depends mainly on the cut-offs of the diagnostic tests.
Aim: To estimate the prevalence of PA in patients with different stages of hypertension based on a dynamic overnight diagnostic test.
Methods: One hundred ninety nine hypertensive patients were divided in 3 groups according to the stage of hypertension, as defined by the European Society of Hypertension. The three groups consisted of 77 patients at stage 1 [systolic blood pressure (SBP) 140 to 159mmHg and/or diastolic blood pressure (DBP) 90 to 100 mmHg], 65 patients at stage 2 (SBP 160 to 179 mmHg and/or DBP 100 to 109 mmHg and 57 patients at stage 3 (SBP ≥180 mmHg and/or DBP≥110 mmHg) respectively. Evaluation of PA was based on the combination of valsartan, captopril and dexamethasone suppression test (DCVT). Post DCVT aldosterone (ALD)>3 ng/dl and post-DCVT aldosterone to renin (ALD/REN) ratio>0.32 ng/dL/μU/mL were applied simultaneously to establish the diagnosis of PA.
Results: The diagnosis of PA using the DCVT test was confirmed in 60 of 199 patients giving a prevalence of 30,1%. The prevalence of PA according to the stage of hypertension was 27,2%(21/77) in patients of stage 1, 27,6%(18/65) in patients of stage 2, and 36,8%(21/57) in stage 3.
Conclusion: Using the DCVT a remarkably increased prevalence of PA (30,1%) was observed. The higher prevalence was observed in patients with severe hypertension (stage 3). Our data suggest that all hypertensive patients, especially those with severe hypertension should be tested for PA.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more